Ann: Phase I Clinical Trial Dosing Update No 1, page-9

I sold out of AGN because if you did any research in Glutamate antagonist and why they fail over the past 2-3 decades is because Glutamate in Brian injury not only causes calcium influx killing neurons but Glutamate in brain injury is also needed within 30 mins of brain injury. It’s why NA-1 created a drug which had a 10 min half life and their new drug has a 30 min half life. AGN has a 12 hour half life. There is a huge possibility that AGN will fail because of this reason

NYR stops only the calcium entering neurons and heart muscle through TRPC channels the first of its kind preventing neuron death and heart muscle death. NYR at this rubbish 20 million dollar valuation should be a 60-120 million market cap peers on safety will happen